Selinex 20 mg (Selinexor) Tablets

Selinexor is an oral anticancer medicine belonging to the selective inhibitor of nuclear export (SINE) class. It is used in specific treatment settings for multiple myeloma and diffuse large B-cell lymphoma (DLBCL), generally when patients have received previous therapies.

Its therapeutic action is related to blocking exportin 1 (XPO1), a protein responsible for transporting various proteins and regulatory factors from the cell nucleus into the cytoplasm. By inhibiting XPO1, selinexor promotes the retention of certain tumor-suppressing proteins inside the nucleus and interferes with cancer-cell survival mechanisms.

Key therapeutic uses may include:

• Treatment of certain cases of relapsed or refractory multiple myeloma
• Treatment of selected patients with relapsed or refractory DLBCL
• Use in combination with other anticancer medicines when specifically indicated
• Management of disease in patients whose cancer has progressed following previous treatment

Treatment selection depends on the cancer type, previous therapies, overall health, laboratory results, and the prescribing specialist's clinical judgment.

Active Ingredient: Selinexor
Strength: 20 mg per tablet
Dosage Form: Film-coated oral tablet
Therapeutic Class: Antineoplastic agent / Selective Inhibitor of Nuclear Export (SINE)

The active pharmaceutical ingredient, selinexor, produces its pharmacological effect through inhibition of the nuclear export protein XPO1.

Inactive ingredients and tablet-coating components can vary according to the specific marketed product and manufacturer. For the exact excipient composition, refer to the official product packaging or prescribing information supplied with the medicine.

The appropriate selinexor dose depends on the specific indication and combination regimen. It should be taken only according to the treatment schedule prescribed by an oncology specialist.

Administration guidance:

• Take the tablets orally with water.
• Swallow the tablet whole; do not crush, chew, or break it unless specifically instructed by a healthcare professional.
• Selinexor may generally be taken with or without food.
• Follow the prescribed dosing days and combination medicines carefully.
• Maintain adequate hydration during treatment unless your doctor has advised otherwise.
• Do not change the dose or treatment schedule without medical supervision.
• Regular blood tests and clinical monitoring may be required during therapy.

Missed Dose:
If a scheduled dose is missed or vomiting occurs after taking a dose, follow the instructions provided by the treating oncology team. Do not take an extra dose to compensate for a missed dose unless specifically instructed.

Important: Selinexor dosing is regimen-specific, and dose reductions or interruptions may be necessary because of adverse reactions or laboratory abnormalities. The patient's oncologist should determine the exact dose and schedule.